The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
R Cunningham, CG Hansen - Clinical Science, 2022 - portlandpress.com
Tumorigenesis is a highly complex process, involving many interrelated and cross-acting
signalling pathways. One such pathway that has garnered much attention in the field of …
signalling pathways. One such pathway that has garnered much attention in the field of …
[HTML][HTML] Non-metabolic enzyme function of pyruvate kinase M2 in breast cancer
Breast cancer (BC) is a prevalent malignant tumor in women, and its incidence has been
steadily increasing in recent years. Compared with other types of cancer, it has the highest …
steadily increasing in recent years. Compared with other types of cancer, it has the highest …
[HTML][HTML] Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer
K Singh, M Pruski, R Bland, M Younes, S Guha… - Laboratory …, 2021 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related
death in the United States. Despite the high prevalence of Kras mutations in pancreatic …
death in the United States. Despite the high prevalence of Kras mutations in pancreatic …
Regulation of alveolar type 2 stem/progenitor cells in lung injury and regeneration
A Wu, H Song - Acta Biochimica et Biophysica Sinica, 2020 - academic.oup.com
The renewal of lung epithelial cells is normally slow unless the lung is injured. The resident
epithelial stem cells rapidly proliferate and differentiate to maintain lung structure and …
epithelial stem cells rapidly proliferate and differentiate to maintain lung structure and …
Ginsenoside Rh2 attenuates the progression of non‐small cell lung cancer by sponging miR‐28‐5p/STK4 axis and inactivating Wnt/β‐catenin signaling
J Ma, D Zhao, D Yu, W Song, X Yang, H Yin - Cancer Medicine, 2023 - Wiley Online Library
Abstract Background Ginsenoside Rh2 (G‐Rh2) exerts anti‐tumor activity in non‐small cell
lung cancer (NSCLC). microRNAs (miRNAs, miRs) play pivotal roles in NSCLC. We aimed …
lung cancer (NSCLC). microRNAs (miRNAs, miRs) play pivotal roles in NSCLC. We aimed …
Hippo kinases MST1/2 regulate immune cell functions in cancer, infection, and autoimmune diseases
Y Wang, A Jia, Y Cao, X Hu, Y Wang… - Critical Reviews™ in …, 2020 - dl.begellhouse.com
Mammalian STE20-like protein kinases (MST), including MST1, MST2, MST3, and MST4,
belong to the germinal center kinase (GCK) family. Kinase MST1/2 is an important …
belong to the germinal center kinase (GCK) family. Kinase MST1/2 is an important …
RASSF effectors couple diverse RAS subfamily GTPases to the Hippo pathway
Small guanosine triphosphatases (GTPases) of the RAS superfamily signal by directly
binding to multiple downstream effector proteins. Effectors are defined by a folded RAS …
binding to multiple downstream effector proteins. Effectors are defined by a folded RAS …
[HTML][HTML] The Hippo pathway: an emerging role in urologic cancers
The Hippo pathway controls several biological processes, including cell growth,
differentiation, motility, stemness, cell contact, immune cell maturation, organ size, and …
differentiation, motility, stemness, cell contact, immune cell maturation, organ size, and …
A method establishment and comparison of in vivo lung cancer model development platforms for evaluation of tumour metabolism and pharmaceutical efficacy
TL Liang, RZ Li, CT Mai, XX Guan, JX Li, XR Wang… - Phytomedicine, 2022 - Elsevier
Background Currently, the identification of accurate biomarkers for the diagnosis of patients
with early-stage lung cancer remains difficult. Fortunately, metabolomics technology can be …
with early-stage lung cancer remains difficult. Fortunately, metabolomics technology can be …
UM-164, a dual inhibitor of c-Src and p38 MAPK, suppresses proliferation of glioma by reducing YAP activity
H Xu, Y Zhang, J Liu, J Cui, Y Gan, Z Wu, Y Chang… - Cancers, 2022 - mdpi.com
Simple Summary UM-164, as a high-potency c-Src inhibitor, is the original lead compound
to be developed for targeting triple-negative breast cancer. Here we validated the fact that …
to be developed for targeting triple-negative breast cancer. Here we validated the fact that …